Clinical Trial Update: Cabozantinib or Paclitaxel in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating cabozantinib versus paclitaxel for persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer; study comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Carcinoma
• Ovarian Carcinoma
• Peritoneal Cancer

Drugs mentioned

• PACLITAXEL (PACLITAXEL)
• cabozantinib (cabozantinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2020-03-10